Pasithea Therapeutics (KTTA) Short term Debt (2022 - 2023)
Pasithea Therapeutics recorded quarterly Short term Debt of $4535.0 in Q2 2023, down 60.5% quarter-over-quarter from $11481.0 in Q1 2023.
Pasithea Therapeutics' Short term Debt history runs 2 years deep, the most recent figure standing at $4535.0 for Q2 2023.
- In Q2 2023, Short term Debt changed N/A year-over-year to $4535.0; the TTM figure through Jun 2023 stood at $4535.0 (changed N/A YoY), while the FY2022 annual figure was $8611.0, changed N/A from the prior year.
- Short term Debt came in at $4535.0 for Q2 2023 at Pasithea Therapeutics, down from $11481.0 in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $11481.0 in Q1 2023 to a low of $4535.0 in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 4,535.00 |
| Mar 31, 2023 | 11,481.00 |
| Dec 31, 2022 | 8,611.00 |